Arginase enzymes in the human prostate: A molecular biological and immunohistochemical approach.
Harrina E RahardjoStefan ÜckertDimitrios TsikasPetter HedlundAndreas BannowskyMarkus A KuczykGeorge T KediaPublished in: Andrologia (2019)
The nitric oxide (NO) pathway plays a role in maintaining the function of the prostate. An impairment in the activity of the NO system may have an impact in the manifestation of lower urinary tract symptomatology and benign prostatic hyperplasia. Arginase enzymes (Arg) counteract the generation of NO by depleting the intracellular pool of L-arginine, known to be the substrate of the NO synthases. This study investigated the expression of arginase type I and II in the human prostate. Nondiseased prostate tissue was obtained during pelvic surgeries (prostatectomy, cystoprostatectomy). Tissue sections were exposed to antibodies directed against Arg I and II, cGMP, the phosphodiesterase 5 and nNOS. The expression of mRNA transcripts encoding for Arg I and Arg II was investigated using molecular biology. Reverse transcriptase polymerase chain reaction (RT-PCR) revealed the presence of mRNA encoding for Arg I and II, immunofluorescence specific for Arg I was seen in the stromal smooth musculature, and labelling for PDE5 and cyclic GMP was also observed. Nerve fibres containing nNOS were identified running across the smooth musculature. Immunostainings for Arg II did not yield signals. These findings are in support of the notion that, in the prostate, Arg is involved in the modulation of the activity of the NO system.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- nitric oxide
- prostate cancer
- nitric oxide synthase
- endothelial cells
- poor prognosis
- urinary tract
- hydrogen peroxide
- induced pluripotent stem cells
- pseudomonas aeruginosa
- rectal cancer
- long non coding rna
- single molecule
- biofilm formation
- escherichia coli
- cystic fibrosis
- robot assisted
- high speed
- candida albicans